Vaderis Therapeutics
Driven to discover. First to deliver.
Basel, Switzerland · Founded 2019 · $171.0M raised
- Headquarters
- Basel
- Employees
- 11–50
- Founded
- 2019
- Business Model
- B2B
- Website
- vaderis.com
- Total Funding
- $171.0M
- Last Round
- $152.0M Series BAug 2026
- Rounds
- 3
About
Vaderis Therapeutics is a Basel, Switzerland-based clinical-stage biopharmaceutical company founded in 2019 to develop targeted therapies for rare vascular diseases caused by vascular malformations. Its lead candidate, engasertib, is in a global Phase 3 study called HEROIC for hereditary hemorrhagic telangiectasia (HHT), and the company closed an oversubscribed $152 million Series B in August 2026 co-led by Goldman Sachs Alternatives and TCGX.
Summary
Vaderis Therapeutics is a Biotech company based in Basel, Switzerland, founded in 2019. It has raised $171.0M in total across 3 rounds, most recently a $152.0M Series B round in Aug 2026. Investors include Medicxi.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Aug 2026
Sign up to see all 3 rounds
Series A through Series B — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Biopharmaceutical services company
Specialty pharmaceutical company
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/vaderis-therapeutics"><img src="https://indexed.vc/api/badge/company/vaderis-therapeutics" alt="Vaderis Therapeutics on Indexed.vc" width="260" height="76" /></a>